Funding for this research was provided by:
National Institutes of Health (R01MH62873)
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (1750102007010)
ZonMw (60-60600-97- 193)
Received: 20 July 2015
Accepted: 14 January 2016
First Online: 2 February 2016
Compliance with ethical standards
: MvL, ML, JWRT, DJH, HvE, APG, AJAMT, CH, BF, NNJR, and JO report no conflict of interest. In the past year, SVF received income, travel expenses and/or research support from Pfizer, Ironshore, Shire, Akili Interactive Labs, Alcobra, VAYA Pharma, Neurovance, Impax and research support from the National Institutes of Health (NIH). His institution is seeking a patent for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. In previous years, he received consulting fees or was on Advisory Boards or participated in continuing medical education programs sponsored by: Shire, Alcobra, Otsuka, McNeil, Janssen, Novartis, Pfizer and Eli Lilly. SVF receives royalties from books published by Guilford Press: Straight Talk about Your Child’s Mental Health and Oxford University Press: Schizophrenia: The Facts. PJH has been in the past 3 years a member of advisory board of Shire and Eli Lilly. JKB has been in the past 3 years a consultant to, member of advisory board of, and/or speaker for: Janssen Cilag BV, Eli Lilly, Bristol-Myer Squibb, Shering Plough, UCB, Shire, Novartis and Servier. He is not an employee of any of these companies, and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, royalties.
: The authors declare all ethical standards procedures were observed and the study was approved by the national ethics committee.